{"url_path":"/sec/kapa/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-022796-index.html","accession_number":"0001493152-26-022796","cik":"0001962011","ticker":"KAPA","issuer_name":"Kairos Pharma, LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-022796-index.html","primary_entity_key":"0001962011","primary_entity_name":"Kairos Pharma, LTD."},"word_count":413,"has_tables":true,"body_markdown":"**Item\n6. Exhibits.**\n\n \n\n**Exhibit**\n\n**Number**\n\n \n**Description**\n\n \n \n \n\n3.1\n \n[Certificate of Incorporation of Kairos Pharma, Ltd. filed with the Secretary of State of the State of Delaware, dated May 10, 2023 (incorporated by reference to Exhibit 3.5 to the Company’s Registration Statement on Form S-1, filed on August 16, 2024).](https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-5.htm)\n\n3.2\n \n[Bylaws of Kairos Pharma, Ltd. (Delaware) (incorporated by reference to Exhibit 3.6 to the Company’s Registration Statement on Form S-1, filed on August 16, 2024).](https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-6.htm)\n\n4.1\n \n[Form of Representative’s Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1, filed on August 16, 2024)](https://www.sec.gov/Archives/edgar/data/1962011/000149315224017318/ex4-1.htm)\n\n10.1*^\n \n[Pharmaceutical Development Services Agreement, dated May 11, 2026, between Kairos Pharma, Ltd. and Brammer Bio MA, LLC](ex10-1.htm)\n\n31.1*\n \n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-1.htm)\n\n31.2*\n \n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-2.htm)\n\n32.1**\n \n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-1.htm)\n\n32.2**\n \n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-2.htm)\n\n101.INS**\n \nInline\nXBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the\nInline XBRL document.\n\n \n \n \n\n101.SCH**\n \nInline\nXBRL Taxonomy Extension Schema.\n\n \n \n \n\n101.CAL*\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase.\n\n \n \n \n\n101.DEF*\n \nInline\nXBRL Taxonomy Extension Definition Linkbase.\n\n \n \n \n\n101.LAB*\n \nInline\nXBRL Taxonomy Extension Label Linkbase.\n\n \n \n \n\n101.PRE*\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase.\n\n \n \n \n\n104*\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).\n\n \n\n*\nFiled herewith.\n\n \n\n**\nFurnished herewith.\n\n \n\n^ Certain portions of this Exhibit have been\nredacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company hereby agrees to furnish supplementally an unredacted copy of\nthe exhibit to the SEC upon its request.\n\n \n\n29\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned, thereunto duly authorized.\n\n \n\nDate:\nMay 13, 2026\n\n \n\n \n**KAIROS\nPHARMA, LTD.**\n\n \n \n \n\n \nBy:\n*/s/\nJohn S. Yu*\n\n \n \nJohn\nS. Yu\n\n \n \nChief\nExecutive Officer and Chairman of the Board of Directors\n\n \n \n(principal\nexecutive officer)\n\n \n \n \n\n \nBy:\n*/s/\nDouglas Samuelson*\n\n \n \nDouglas\nSamuelson\n\n \n \nChief\nFinancial Officer\n\n \n \n(Principal\nFinancial and Accounting Officer)\n\n \n\n30"}